(CME accreditation by DHA in process)

The treatment of type 2 diabetes mellitus has evolved in the present century toward safer and more effective treatments, which in some cases can also reduce the risk of hypoglycemia, cardiovascular disease and renal outcomes.  New glucose-lowering drugs acting on novel pathways, as well as new formulations, have been developed, licensed and launched, many of which provide new options for the management of type 2 diabetes.  However, there is a rising prevalence of type 2 diabetes and its associated comorbidities, posing new challenges for health care practitioners.  These challenges are that much more demanding during the unprecedented COVID-19 pandemic.

This interactive webinar will review the novel mechanisms of action and pharmacokinetics of these agents and will also address how reaching appropriate therapeutic goals for the type 2 diabetes patient is possible. Four short presentations by prominent leaders in the fields of endocrinology and cardiology will focus on topics that will enable practitioners to implement new therapeutic strategies. To read more about the content to be presented, check out the blog entries and submit your comments and questions. These will be addressed during the live webinar during the question-and-answer session.

• Recognize the association between glycemic variability as a predictor of hypoglycemia, the clinical
  implications of hypoglycemia in type 2 diabetes patients, and proven approaches to its prevention
• Explain the role of fixed dose combination therapy and when and how it is appropriate to adjust insulin therapy in type 2 diabetes patients, as well as manage clinical inertia
• Implement new treatment strategies with evidence provided by recent cardiovascular outcomes trials that highlight new therapies that have a demonstrated decrease in cardiovascular risk
• Understand the special considerations for patients with type 2 diabetes in light of the COVID-19 pandemic